© 2004 by European Society of Cardiology
Copyright © 2003, European Society of Cardiology
Inhibition of Rho-kinase protects the heart against ischemia/reperfusion injury
aDepartments of Investigative and Cardiac Biology (UW-2510), GlaxoSmithKline Pharmaceuticals, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939, USA
bVascular Inflammatory Diseases, GlaxoSmithKline Pharmaceuticals, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939, USA
cDepartment of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA 19107-5004, USA
dSafety Assessment, GlaxoSmithKline Pharmaceuticals, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939, USA
* Corresponding author. Tel.: +1-610-270-5366; fax: +1-610-270-5080. weike_2_bao{at}gsk.com
Objective: To investigate the role of Rho A and Rho-kinase in acute myocardial ischemia/reperfusion injury and the protective effect of Rho-kinase inhibitor, Y-27632 [(R)-(+)-trans-N-(4-pyridyl)-4-(1-aminoethyl)cyclohexanecarboxamide]. Methods and results: Male CD1 mice were subjected to 30 min of coronary occlusion and 24 h reperfusion. Ischemia/reperfusion upregulated expression of Rho A in ischemic myocardium, and subsequently activated Rho-kinase. Y-27632 significantly inhibited the activation of Rho-kinase following ischemia/reperfusion. Treatment with Y-27632 at 10 and 30 mg/kg oral administration, reduced infarct size by 30.2% and 41.1%, respectively (P<0.01 vs. vehicle). Y-27632 also enhanced post-ischemia cardiac function. Left ventricular systolic pressure, +dP/dt and –dP/dt were significantly improved by 23.5%, 52.3%, and 59.4%, respectively (P<0.01 vs. vehicle). Moreover, Y-27632 reduced ischemia/reperfusion-induced myocardial apoptosis. The apoptotic myocytes in ischemic myocardium after 4 h reperfusion were reduced from 13.1% in vehicle group to 6.4% in Y-27632-treated group (P<0.01). Meanwhile, ischemia/reperfusion-induced downregulation of Bcl-2 in myocardium was remarkably attenuated in the treated animals. Ischemia/reperfusion resulted in remarkable elevation in serum levels of proinflammatory cytokines, interleukin-6 (IL-6), keratinocyte chemoattractant (KC) and granulocyte colony-stimulating factor (G-CSF), which was significantly suppressed by Y-27632. In addition, Y-27632 decreased ischemia/reperfusion-induced accumulation of neutrophils in the heart by 45% (P<0.01). Conclusions: These results suggest that Rho-kinase plays a pivotal role in myocardial ischemia/reperfusion injury. The cardiac protection provided by treatment with a selective Rho-kinase inhibitor is likely via anti-apoptotic effect and attenuation of ischemia/reperfusion-induced inflammatory responses. The finding of this study suggest a novel therapeutic approach to the treatment of acute myocardial ischemia/reperfusion injury.
KEYWORDS Mouse; Ischemia; Reperfusion; Infarction; Apoptosis
Time for primary review 00 days
This work was presented at AHA 2003 meeting, Orlando, FL, USA.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
C. Meyer-Schwesinger, S. Dehde, C. von Ruffer, S. Gatzemeier, P. Klug, U. O. Wenzel, R. A. K. Stahl, F. Thaiss, and T. N. Meyer Rho kinase inhibition attenuates LPS-induced renal failure in mice in part by attenuation of NF-{kappa}B p65 signaling Am J Physiol Renal Physiol, May 1, 2009; 296(5): F1088 - F1099. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. P. Del Re, S. Miyamoto, and J. H. Brown Focal Adhesion Kinase as a RhoA-activable Signaling Scaffold Mediating Akt Activation and Cardiomyocyte Protection J. Biol. Chem., December 19, 2008; 283(51): 35622 - 35629. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kobayashi, Y. Tanoue, M. Eto, H. Baba, S. Kimura, S. Oda, K. Taniguchi, and R. Tominaga A Rho-kinase inhibitor improves cardiac function after 24-hour heart preservation. J. Thorac. Cardiovasc. Surg., December 1, 2008; 136(6): 1586 - 1592. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. P. Ongusaha, H. H. Qi, L. Raj, Y.-B. Kim, S. A. Aaronson, R. J. Davis, Y. Shi, J. K. Liao, and S. W. Lee Identification of ROCK1 as an Upstream Activator of the JIP-3 to JNK Signaling Axis in Response to UVB Damage Sci. Signal., November 25, 2008; 1(47): ra14 - ra14. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Prakash, M. H. de Borst, M. Lacombe, F. Opdam, P. A. Klok, H. van Goor, D. K.F. Meijer, F. Moolenaar, K. Poelstra, and R. J. Kok Inhibition of Renal Rho Kinase Attenuates Ischemia/Reperfusion-Induced Injury J. Am. Soc. Nephrol., November 1, 2008; 19(11): 2086 - 2097. [Abstract] [Full Text] [PDF] |
||||




